background
ebola
viru
caus
hemorrhag
fever
syndrom
associ
high
mortal
human
absenc
effect
therapi
ebola
viru
infect
develop
vaccin
becom
import
strategi
contain
outbreak
immun
dna
andor
replicationdefect
adenovir
vector
rad
encod
ebola
glycoprotein
gp
nucleoprotein
np
previous
shown
confer
specif
protect
immun
nonhuman
primat
gp
exert
cytopath
effect
transfect
cell
vitro
multipl
gp
form
identifi
natur
rais
question
would
optim
human
vaccin
address
question
explor
efficaci
mutant
gp
multipl
ebola
viru
strain
reduc
vitro
cytopath
analyz
protect
effect
primat
challeng
model
without
np
delet
gp
transmembran
domain
elimin
vitro
cytopath
reduc
protect
efficaci
least
one
order
magnitud
contrast
point
mutat
identifi
abolish
cytopath
retain
immunogen
confer
immun
protect
absenc
np
minim
effect
rad
dose
establish
particl
two
log
lower
use
previous
epidem
ebola
viru
hemorrhag
fever
result
fatal
ill
major
patient
becom
infect
casefat
rate
near
studi
patient
surviv
infect
indic
compon
adapt
immun
system
activ
infect
survivor
suggest
vaccin
target
popul
could
significantli
reduc
mortal
exposur
ebola
viru
previous
describ
vaccin
elicit
strong
adapt
immun
respons
uniformli
protect
nonhuman
primat
highdos
challeng
zair
ebolaviru
zebov
singl
immun
vector
deriv
adenoviru
type
contain
ebola
glycoprotein
gp
nucleoprotein
np
gene
elicit
protect
immun
respons
within
mo
strength
vector
use
vaccin
deriv
abil
elicit
rapid
immun
due
high
insert
express
level
natur
target
dendrit
cell
may
enhanc
antigen
present
moreov
use
replicationdefect
viral
vector
gene
deliveri
desir
safeti
perspect
product
develop
human
use
beyond
consider
vector
choic
select
target
viral
antigen
must
incorpor
determin
rel
magnitud
protect
immun
elicit
differ
insert
breadth
protect
across
viru
subtyp
ebola
viru
compris
four
speci
zebov
sudan
ebolaviru
sebov
ivori
coast
reston
zebov
sebov
contribut
highest
mortal
natur
outbreak
therefor
zair
sudan
gulu
ebolavirus
select
studi
sought
provid
basi
select
human
vaccin
candid
identifi
optim
vaccin
composit
respect
antigen
strength
immun
protect
nonhuman
primat
ebola
np
includ
vaccin
highli
conserv
among
ebola
subtyp
found
elicit
strong
cellular
immun
respons
anim
model
reagent
use
studi
produc
crucel
leiden
netherland
follow
organ
econom
cooper
develop
principl
good
laboratori
practic
guidanc
use
method
similar
design
easi
scaleup
gmp
clinicalgrad
prepar
gp
point
mutant
vector
current
prepar
clinic
trial
replicationincompet
vector
gener
cell
use
adaptor
plasmid
padapt
togeth
cosmid
essenti
describ
elsewher
adaptor
plasmid
contain
left
portion
genom
nucleotid
follow
transcript
control
element
adaptor
dna
region
nucleotid
ebola
gpencod
gene
clone
express
cassett
adaptor
plasmid
transcript
control
human
fulllength
immediateearli
cmv
promot
polyadenyl
signal
adenovirus
contain
ebola
gp
gpdtm
point
mutat
gener
cotransfect
linear
padaptebola
gp
plasmid
togeth
linear
cosmid
contain
right
portion
genom
cell
use
lipofectamin
invitrogen
carlsbad
california
unit
state
cell
cultur
dmem
supplement
fetal
bovin
serum
gibco
san
diego
california
unit
state
incub
humidifi
atmospher
co
homolog
recombin
led
gener
gp
virus
adenovir
vector
crude
lysat
plaquepurifi
use
limit
dilut
agar
overlay
ad
vector
clone
analyz
presenc
express
transgen
posit
clone
amplifi
largescal
product
use
cell
triplelay
cm
flask
virus
purifi
standard
twostep
cscl
gradient
ultracentrifug
subsequ
desalt
formul
three
consecut
dialysi
step
trishcl
ph
contain
glycerol
purifi
ad
vector
store
singl
use
aliquot
viru
particl
titer
determin
anionexchang
hplc
base
describ
procedur
infect
assess
use
cell
adenovirusmedi
ebola
gp
express
assess
infect
cell
follow
analysi
cultur
lysat
western
blot
ident
purifi
vector
confirm
pcr
express
vector
pgp
pdtm
point
mutant
contain
cmv
enhanc
promot
describ
pdtm
contain
delet
amino
acid
creat
digest
bspmi
klenow
fuse
tga
result
plasmid
also
contain
four
extra
amino
acid
aa
c
terminu
maa
cell
deriv
tagexpress
cell
line
cultur
dmem
supplement
fetal
bovin
serum
gibco
transfect
measur
protein
express
cell
round
perform
cell
lg
dna
per
well
sixwel
plate
use
calcium
phosphat
invitrogen
accord
manufactur
instruct
protein
express
cell
supernat
lysat
evalu
sdspage
follow
western
blot
gpspecif
polyclon
antibodi
kindli
provid
sanchez
center
diseas
control
atlanta
georgia
unit
state
comparison
secret
cellular
express
level
measur
respect
total
sampl
volum
cynomolgu
macaqu
macaca
fasciculari
age
weigh
kg
obtain
covanc
princeton
new
jersey
unit
state
use
immun
challeng
experi
treatment
group
contain
three
anim
unless
state
otherwis
prevent
unnecessari
use
anim
one
unvaccin
control
includ
studi
cumul
studi
period
control
use
viru
seed
stock
administ
rout
dose
lethal
anim
mean
time
death
monkey
hous
singli
anesthet
ketamin
obtain
blood
specimen
administ
vaccin
conduct
research
investig
adher
version
anim
care
usag
guid
prepar
institut
laboratori
anim
resourc
facil
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
anim
receiv
regular
enrich
ebola
viru
challeng
end
experi
anim
maintain
maximum
contain
laboratori
fed
check
daili
cynomolgu
macaqu
inject
intramuscularli
ml
equal
mixtur
immunogen
dose
indic
viral
challeng
perform
inocul
anim
left
right
caudal
thigh
ml
viral
stock
contain
target
dose
plaqueform
unit
pfu
zebov
wk
initi
immun
advers
effect
adenoviru
vaccin
observ
acut
ebola
viru
stock
use
studi
origin
obtain
fatal
infect
human
former
zair
collect
serum
blood
viral
load
elisa
titer
perform
previous
describ
surviv
anim
follow
least
wk
postchalleng
transfect
cell
collect
incub
pb
contain
mm
edta
incub
control
ig
rabbit
antisgpgp
serum
gener
provid
dr
sanchez
cdc
min
ice
cell
wash
twice
icecold
pb
contain
fetal
bovin
serum
incub
fitcor
peconjug
secondari
antibodi
jackson
immunoresearch
laboratori
west
grove
pennsylvania
unit
state
sigmaaldrich
st
loui
missouri
unit
state
respect
min
ice
follow
wash
analysi
conduct
use
bectondickinson
fourcolor
calibur
flow
cytomet
flowjo
analysi
softwar
tree
star
ashland
oregon
unit
state
nuncimmuno
maxisorp
plate
nunc
rochest
new
york
unit
state
coat
llwell
lg
ml
lectin
galanthu
nivali
sigmaaldrich
pb
incub
overnight
incub
carri
room
temperatur
plate
block
h
pb
contain
fetal
calf
serum
wash
twice
tween
sigmaaldrich
pb
ebola
gp
obtain
supernat
cell
transfect
mammalian
express
plasmid
ebola
gp
dtm
ad
plate
concentr
mgml
total
protein
llwell
plate
wash
six
time
pb
contain
tween
test
sera
dilut
pb
contain
tween
fetal
calf
serum
allow
react
agcoat
well
min
wash
plate
six
time
goat
antihuman
igg
chemicon
temecula
california
unit
state
conjug
horseradish
peroxidas
use
detect
antibodi
bound
igg
detect
sigma
fast
ophenylenediamin
dihydrochlorid
tablet
set
sigmaaldrich
optic
densiti
determin
panel
normal
sera
run
time
assay
perform
ebola
gp
z
pseudotyp
lentivir
virion
produc
previous
describ
briefli
cell
plate
densiti
per
diamet
tissu
cultur
dish
transfect
next
day
calcium
phosphat
reagent
invitrogen
cmvr
ebola
gp
z
plasmid
dna
cell
transfect
overnight
wash
replenish
fresh
medium
supernat
contain
pseudotyp
viru
harvest
h
later
filter
pores
syring
filter
store
aliquot
neutral
assay
perform
huvec
cambrex
east
rutherford
new
jersey
unit
state
plate
plate
prior
infect
viru
stock
titrat
infecti
dose
incub
h
presenc
serum
immun
cynomolgu
macaqu
cultur
media
remov
cell
replac
virusserum
peripher
blood
mononuclear
cell
isol
cynomolgu
macaqu
whole
blood
sampl
separ
ficol
approxim
cell
stimul
rpmi
medium
gibco
h
antibodi
brefeldin
either
dmso
pool
peptid
span
zebov
gp
mayinga
strain
open
read
frame
full
length
virionbound
form
total
overlap
span
entir
ebola
glycoprotein
final
concentr
lgml
cell
fix
permeabil
fac
lyse
becton
dickinson
palo
alto
california
unit
state
supplement
tween
stain
mixtur
fluorescenceconjug
antibodi
lineag
marker
tnf
sampl
run
fac
calibur
fac
aria
flow
cytomet
analyz
use
softwar
flowjo
posit
gate
lymphocyt
use
forward
versu
side
scatter
follow
gate
specif
popul
defin
posit
respect
cytokineposit
cell
defin
percentag
within
individu
lymphocyt
subset
least
event
analyz
sampl
develop
optim
ebola
vaccin
use
rad
vector
first
analyz
mutant
form
gp
transmembran
domain
remov
although
previous
report
delet
mucin
domain
elimin
cytotox
delet
remov
nearli
aa
elimin
mani
potenti
b
cell
epitop
previou
data
suggest
vitro
cytopath
effect
gp
may
mediat
near
cell
surfac
requir
transmembran
anchor
protein
altern
approach
elimin
gpinduc
cytopath
effect
therefor
explor
remov
aa
put
transmembran
cytoplasm
domain
diminish
immun
protect
mutant
gp
lack
transmembran
anchor
domain
gp
protein
readili
detect
supernat
cell
transfect
transmembranedelet
vector
dtm
z
confirm
secret
contrast
supernat
cell
transfect
wildtyp
gp
z
figur
furthermor
synthesi
two
previous
defin
form
gp
gener
posttransl
process
readili
detect
compar
level
delet
transmembran
domain
elimin
gpinduc
cytopath
transfect
cell
contrast
wildtyp
gp
figur
total
dtm
express
equival
wildtyp
protein
level
figur
determin
whether
dtm
mutant
zebov
could
protect
infecti
ebola
challeng
cynomolgu
macaqu
immun
rad
vector
encod
np
either
dtm
z
gp
z
immun
gp
z
np
protect
anim
vaccin
either
adenovir
particl
challeng
pfu
zebov
later
figur
contrast
surviv
frequenc
decreas
anim
receiv
dtm
z
vaccin
group
vaccin
adenovir
particl
protect
immun
decreas
indic
substanti
decreas
efficaci
anim
vaccin
dtm
np
versu
gp
np
p
separ
experi
unpublish
data
particl
dtm
alon
fail
protect
infect
analysi
cellmedi
immun
respons
show
gpspecif
tcell
respons
present
major
anim
wk
postimmun
figur
left
middl
panel
respect
correl
well
npspecif
b
immun
respons
immun
anim
left
middl
graph
intracellular
flow
cytometri
perform
quantifi
tnfa
product
ebolaspecif
lymphocyt
respect
anim
immun
indic
group
contain
three
point
due
technic
error
one
sampl
immun
respons
measur
wk
postimmun
circl
diamond
squar
triangl
indic
respons
individu
anim
horizont
line
indic
averag
individu
respons
immun
group
result
repres
percent
cytokineposit
gate
lymphocyt
group
background
stimul
dmso
alon
subtract
sampl
elisa
titer
ebola
gpspecif
antibodi
sera
vaccin
anim
collect
week
postimmun
right
graph
elisa
result
repres
endpoint
dilut
titer
determin
optic
densiti
describ
method
doi
cellular
respons
unpublish
data
antigenspecif
cellular
respons
measur
intracellular
cytokin
tumor
necrosi
factora
tnfa
secret
indistinguish
gp
z
dtm
z
vaccin
anim
similarli
humor
immun
respons
measur
antiebola
gp
elisa
igg
titer
compar
vaccin
anim
figur
right
graph
neutral
antibodi
titer
low
absent
surviv
anim
unpublish
data
result
suggest
delet
gp
transmembran
domain
reduc
vaccin
efficaci
readili
appar
correl
protect
previou
experi
log
decreas
dose
gp
z
np
vaccin
protect
comparison
previou
studi
use
rad
particl
establish
lowest
dose
adenovir
vector
would
afford
protect
ebola
infect
doserespons
analysi
perform
anim
immun
rad
vector
encod
gp
z
np
increas
dose
particl
per
anim
surviv
group
receiv
dose
greater
wherea
challeng
infect
uniformli
lethal
dose
group
figur
ebola
viru
isol
plasma
plaqu
assay
vero
cell
neg
surviv
anim
unpublish
data
plasma
could
theori
contain
factor
immunoglobulin
cytokin
could
imped
viru
replic
method
rtpcr
could
potenti
use
detect
viru
neg
signal
assay
conclus
steril
immun
clear
correl
viremia
mortal
establish
nonhuman
primat
model
ebola
viru
infect
surviv
therefor
use
studi
endpoint
experi
prechalleng
cell
respons
tnfa
unremark
report
previous
immun
cynomolgu
macaqu
figur
cell
respons
similar
across
vaccin
dose
group
except
higher
respond
immun
rad
particl
antigenspecif
igg
also
gener
immun
anim
level
equival
among
anim
group
surviv
ebola
viru
challeng
figur
left
graph
howev
differ
one
log
p
igg
level
survivor
immun
particl
fatal
immun
rad
particl
suggest
level
may
correl
protect
immun
regimen
contrast
neutral
antibodi
titer
gp
differ
significantli
survivor
fatal
figur
right
graph
suggest
elisa
igg
titer
may
stronger
predictor
protect
immun
vaccin
result
indic
threshold
immun
protect
lie
rad
particl
therefor
subsequ
experi
carri
use
dose
increas
sensit
detect
differ
antigen
strength
variou
immunogen
sought
identifi
mutant
gp
exhibit
cytopath
effect
yet
retain
nativ
antigen
structur
express
vitro
rel
conserv
region
figur
b
immun
respons
immun
anim
intracellular
flow
cytometri
perform
quantifi
tnfa
product
ebolaspecif
left
graph
right
graph
lymphocyt
respect
anim
immun
indic
immun
respons
measur
wk
postimmun
circl
diamond
squar
indic
respons
individu
anim
horizont
line
indic
averag
individu
respons
immun
group
result
repres
percent
cytokin
posit
gate
lymphocyt
group
background
stimul
dmso
alon
subtract
sampl
pvalu
obtain
use
unpair
student
ttest
ns
signific
c
antibodi
respons
immun
anim
antigp
elisa
titer
left
graph
serum
neutral
antibodi
respons
right
graph
measur
describ
method
doi
gp
identifi
point
mutat
systemat
introduc
gp
protein
bear
singleamino
acid
chang
screen
decreas
induct
cell
round
wildtyp
level
express
reactiv
conformationdepend
antibodi
substitut
aspart
glutam
acid
posit
ie
ebola
gp
zair
sudangulu
speci
z
sg
respect
abolish
cellround
phenotyp
transfect
cell
alter
protein
express
reactiv
antibodi
whose
bind
properti
sensit
chang
protein
conform
figur
mutant
evalu
abil
induc
protect
immun
alon
combin
np
compar
wildtyp
gpnp
immunogen
zair
sudangulu
combin
np
surviv
cynomolgu
macaqu
immun
group
diminish
respect
figur
contrast
complet
protect
achiev
anim
immun
z
sg
anim
receiv
wildtyp
gp
z
np
ebola
gpspecif
respons
lymphocyt
detect
intracellular
stain
tnfa
show
statist
signific
differ
popul
differ
immun
group
figur
left
graph
similarli
individu
differ
respons
correl
surviv
although
trend
toward
diminish
surviv
group
lower
antigenspecif
cellular
respons
figur
middl
graph
antigenspecif
elisa
igg
correl
well
surviv
doserang
experi
also
stimul
immun
anim
figur
right
graph
result
experi
illustr
np
may
necessari
protect
immun
ebola
infect
may
diminish
protect
combin
modifi
gp
immunogen
lower
limit
protect
vaccin
dose
ebola
viru
outbreak
associ
high
lethal
due
absenc
treatment
option
licens
vaccin
dna
prime
rad
vector
boost
rad
alon
confer
protect
lethal
challeng
anim
model
close
parallel
human
diseas
rad
vector
vaccin
confer
protect
acceler
vaccin
regimen
nonhuman
primat
speci
although
vitro
cytopath
observ
overexpress
ebola
gp
one
vaccin
compon
seen
toxic
anim
vaccin
vector
express
ebola
gp
unpublish
data
howev
hypothet
complic
rais
sought
modifi
gp
elimin
vitro
cytopath
yet
retain
antigen
properti
necessari
protect
immun
efficaci
differ
form
gp
evalu
use
dose
threshold
protect
acceler
vaccin
model
identifi
vaccin
decreas
vitro
cytopath
retain
immunogen
necessari
protect
ebola
infect
find
altern
form
gp
confer
differenti
immun
protect
delet
gp
transmembran
domain
abolish
cytopath
effect
transfect
cell
correspond
dtm
z
vaccin
less
efficaci
wildtyp
gp
z
protect
cynomolgu
macaqu
infect
although
cellular
humor
immun
respons
indistinguish
group
receiv
differ
immunogen
form
inher
variabl
quantit
respons
outbr
macaqu
may
obscur
abil
identifi
immun
respons
respons
higher
surviv
altern
dtm
z
may
differ
wildtyp
gp
z
antigen
qualiti
captur
measur
total
antigenspecif
igg
intracellular
cytokin
respons
stimul
broad
peptid
pool
exampl
transmembranedelet
protein
secret
like
show
conform
differ
membraneanchor
protein
subsequ
modif
glycoprotein
retain
membran
attach
nativ
envelop
structur
yield
mutant
reduc
vitro
cytopath
recent
suggest
region
gp
contribut
viral
receptor
bind
noteworthi
envelop
glycoprotein
cytopath
virus
hiv
link
receptor
bind
fusion
rais
possibl
ebola
gp
share
similar
properti
ongo
outbreak
ebola
marburg
virus
illustr
import
develop
filoviru
vaccin
human
use
report
show
protect
immun
ebola
infect
achiev
nonhuman
primat
gener
antigenspecif
immun
respons
singl
protein
gp
modifi
elimin
vitro
cytopath
effect
sinc
vaccin
licens
initi
one
agent
protect
immun
evalu
challeng
speci
zair
ebolaviru
futur
studi
address
whether
vaccin
protect
ebola
speci
sebov
preliminari
studi
suggest
protect
observ
anim
receiv
bival
vaccin
surviv
zebov
challeng
subsequ
expos
gulu
strain
sebov
unpublish
data
howev
complet
analysi
question
crossstrain
protect
requir
addit
studi
fall
beyond
scope
present
studi
doserang
experi
rad
express
gp
np
immun
protect
correl
well
gpspecif
elisa
igg
titer
observ
consist
earli
ebola
vaccin
studi
perform
use
genebas
gp
np
vaccin
guinea
pig
current
studi
also
trend
toward
increas
surviv
anim
higher
cell
respons
vaccin
contain
differ
antigen
combin
evalu
protect
efficaci
combin
find
suggest
gpspecif
humor
immun
respons
provid
correl
immun
howev
like
cell
respons
contribut
protect
ig
respons
may
reflect
cell
help
improv
sensit
cell
assay
well
immun
deplet
studi
may
provid
insight
question
ebola
viru
protect
immun
also
achiev
recent
use
replic
compet
vesicular
stomat
viru
vector
support
concept
vaccin
ebola
success
protect
diseas
mortal
vaccin
merit
investig
replicationcompet
virus
contribut
mani
effect
vaccin
concern
remain
live
virus
amount
viral
replic
control
environment
effect
uncertain
consider
may
pose
challeng
develop
vesicular
stomat
virusbas
vaccin
human
use
recent
recommend
liveattenu
polio
vaccin
rel
safe
vaccin
longer
use
unit
state
inactiv
viru
use
instead
exemplifi
challeng
contrast
rad
vector
vaccin
nonrepl
manufactur
high
yield
safeti
data
exist
platform
show
immun
follow
singl
inject
rad
particl
dose
two
order
magnitud
lower
previous
report
singlemod
vaccin
dose
rad
vector
prove
well
toler
immunogen
recombin
gene
vivo
evalu
vector
report
alon
dna
primerad
boost
combin
one
theoret
concern
regard
rad
vaccin
possibl
preexist
immun
natur
infect
occur
us
popul
may
affect
vaccin
efficaci
recent
preliminari
result
hiv
vaccin
trial
suggest
antigenspecif
immun
respons
readili
elicit
vector
even
studi
particip
prior
immun
adenoviru
type
especi
vaccin
dose
higher
use
unpublish
data
given
ebola
gp
immunogen
hiv
env
would
expect
signific
immun
respons
gener
present
vaccin
futur
clinic
trial
resolv
question
addit
dna
prime
use
prior
rad
boost
overcom
ad
immun
also
shown
effect
prevent
ebola
infect
case
immun
becom
problemat
sever
altern
rad
platform
involv
exot
serotyp
develop
preexist
immun
quit
low
worldwid
principl
report
paper
would
appli
develop
vaccin
candid
immun
rad
particl
z
g
effect
infecti
challeng
zebov
data
provid
evid
protect
requir
inclus
np
gene
vaccin
document
protect
immun
confer
respons
gp
antigen
alon
inde
diminish
surviv
observ
vaccin
group
contain
gene
rais
possibl
condit
inclus
np
may
dilut
protect
immun
respons
howev
signific
result
limit
rel
small
anim
number
use
noteworthi
elimin
np
vaccin
dose
reduct
rad
particl
diminish
protect
simplifi
vaccin
futur
develop
human
trial
firstgener
ebola
dna
vaccin
current
evalu
phase
clinic
studi
rad
compon
current
manufactur
clinic
grade
prepar
undergo
safeti
studi
test
phase
trial
pend
regulatori
approv
complet
initi
studi
test
individu
dna
rad
vaccin
compon
candid
evalu
prime
boost
combin
vaccin
safeti
immunogen
rel
nonhuman
primat
challeng
model
guid
assess
regard
util
prevent
vaccin
human
altern
languag
abstract
translat
abstract
french
found
doi
kb
doc
background
human
get
infect
ebola
viru
develop
ill
call
ebola
hemorrhag
fever
ehv
one
deadli
viral
diseas
known
ill
patient
die
avail
treatment
ehv
scientist
think
occasion
outbreak
diseas
occur
viru
jump
infect
anim
person
rare
event
transmit
peopl
direct
contact
infect
blood
bodi
fluid
part
sever
strain
variant
ebola
viru
exist
outbreak
caus
either
zair
strain
sudan
gulu
strain
socal
particular
viru
first
isol
scientist
work
vaccin
ebola
could
given
peopl
get
infect
protect
come
contact
viru
number
candid
vaccin
develop
test
anim
studi
done
research
studi
work
vaccin
consist
two
particular
part
viru
one
part
call
gp
stand
glycoprotein
outer
coat
viru
np
nucleoprotein
insid
without
rest
viru
gp
np
caus
ebv
howev
hope
give
part
viru
individu
educ
immun
system
build
respons
gp
np
would
recogn
viru
vaccin
person
becom
infect
whole
viru
destroy
caus
diseas
get
gp
np
part
bodi
caus
strong
immun
respons
effect
vaccin
research
use
manmad
version
anoth
harmless
viru
call
recombin
adenoviru
carri
np
gp
research
shown
previous
strategi
introduc
vaccin
work
anim
vaccinei
combin
viru
two
ebola
viru
partscan
protect
anim
subsequ
infect
real
ebola
viru
would
otherwis
kill
howev
earlier
studi
research
notic
gp
part
present
high
level
seem
make
human
cell
sick
seen
similar
problem
experiment
anim
safe
side
decid
see
whether
could
chang
gp
part
would
still
effect
vaccin
longer
make
human
cell
sick
research
find
chang
gp
part
vaccin
differ
way
would
longer
make
human
cell
sick
test
whether
result
vaccin
combin
origin
np
part
viru
could
still
protect
monkey
ehf
infect
ebola
viru
found
new
gp
version
made
vaccin
less
effect
other
hope
name
gave
level
protect
origin
gp
part
present
experi
research
also
found
np
compon
seem
unnecessari
case
even
weaken
vaccin
effect
find
mean
research
develop
simplifi
vaccin
ebola
viru
effect
monkey
vaccin
consist
modifi
gp
compon
well
toler
human
cell
even
high
concentr
compon
vaccin
candid
current
develop
ebola
seem
like
one
test
human
volunt
near
futur
initi
clinic
trial
test
whether
vaccin
safe
human
whether
caus
immun
system
produc
immun
respons
specif
ebola
viru
assum
outcom
trial
posit
next
question
whether
vaccin
protect
human
ebola
diseas
ebola
danger
outbreak
rel
rare
vaccin
like
test
actual
outbreak
time
experiment
vaccin
might
given
peopl
immedi
risk
becom
infect
especi
healthcar
worker
take
care
infect
patient
high
risk
becom
infect
addit
trial
human
scientist
also
explor
whether
vaccin
develop
base
gp
compon
zair
strain
protect
monkey
infect
strain
ebola
viru
